Relevant bibliographies by topics / Opioid-tolerant

Academic literature on the topic 'Opioid-tolerant'

Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Opioid-tolerant.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Opioid-tolerant"

1

Gulur, Padma, and Amanda H. Nelli. "The Opioid-Tolerant Patient: Opioid Optimization." Journal of Arthroplasty 35, no. 6 (June 2020): S50—S52. http://dx.doi.org/10.1016/j.arth.2020.01.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Lee, PharmD, Stephanie, Vineet Tatla, PharmD, Sorin Buga, MD, and Doreen Pon, PharmD, BCOP, BCPS. "Comparing the safety and efficacy of intravenous naloxone administration in opioid-naive and opioid-tolerant hospitalized oncology patients." Journal of Opioid Management 18, no. 6 (November 1, 2022): 497–502. http://dx.doi.org/10.5055/jom.2022.0744.

Full text
Abstract:
Objective: To compare naloxone doses and clinical outcomes after emergency opioid reversal in opioid-naïve and opioid-tolerant inpatients.Design: Cross-sectional, retrospective chart review.Setting: Comprehensive cancer center.Patients: In-patients who received ≥1 dose of intravenous naloxone for emergency opioid reversal between 2014 and 2018.Methods: Patients were classified as opioid-tolerant based on opioid dosing history ≥60 morphine milligram equivalents/day for ≥7 consecutive days prior to naloxone administration. Response to naloxone was based on documentation of improvement in respiratory rate to 10 breaths/min or improved response to stimuli.Outcomes: Naloxone doses and clinical outcomes after naloxone administration.Results: Ninety-three naloxone episodes (58 opioid-naive and 35 opioid-tolerant) in 80 unique patients were included. No differences between opioid-naïve and opioid-tolerant groups were found for naloxone mean starting doses (0.14 mg vs 0.19 mg, p = 0.35), total doses (0.50 mg vs 0.32 mg, p = 0.07), and response rates (74.1 percent vs 77.1 percent, p = 0.81). Naloxone adverse reactions were more frequent in the opioid-tolerant group than the opioid-naïve group (opioid withdrawal symptoms (OWSs): 14.3 percent vs 0 percent; increase in pain: 20 percent vs 8.6 percent, p = 0.002).Conclusions: In opioid-tolerant patients, naloxone total doses required and response rates were similar to opioid-naïve patients. Use of opioid dosing history to identify potentially opioid-dependent patients should be considered prior to naloxone administration to guide dosing and reduce the risk for precipitating OWSs.
APA, Harvard, Vancouver, ISO, and other styles
3

Gulur, Padma. "Opioid Tolerance – A Predictor of Increased Length of Stay and Higher Readmission Rates." Pain Physician 4;17, no. 4;7 (July 14, 2014): E503—E507. http://dx.doi.org/10.36076/ppj.2014/17/e503.

Full text
Abstract:
The increasing use of opioids to manage pain in the United States over the last decade has resulted in a subset of our population developing opioid tolerance. While the management of opioid tolerant patients during acute episodes of care is well known to be a challenge amongst health care providers, there is little in the literature that has studied opioid tolerance as a predictor of outcomes. We conducted a review on all admissions to Massachusetts General Hospital over a period of 6 months, from January 2013 to June 2013, and identified opioid tolerant patients at admission using the FDA definition of opioid tolerance. To compare risk adjusted groups, we placed opioid tolerant patients and control patients into groups determined by expected length of stay of less than 2 days, 2 to 5 days, 5 to 10 days, and greater than 10 days. Opioid tolerant patients were then compared to the control for outcomes measures including observed length of stay and readmission rates. Our results show that all opioid tolerant patients have a significantly longer length of stay and a greater 30 day all cause readmission rate than the control group (P < 0.01). This trend was found in the first 3 risk adjusted groups, but not in the fourth group where expected length of stay was greater than 10 days. The opioid tolerant population is at risk given the poorer outcomes and higher health care costs associated with their care. It is imperative that we identify opportunities for improvement and delineate specific pathways for the care of these patients. Key words: Opioid tolerance, opioid tolerant patient population, opioid tolerant patients, readmission rates, length of stay
APA, Harvard, Vancouver, ISO, and other styles
4

Sazuka, Shoichiro, and Toshiya Koitabashi. "Tapentadol is effective in the management of moderate-to-severe cancer-related pain in opioid-naïve and opioid-tolerant patients: a retrospective study." Journal of Anesthesia 34, no. 6 (July 9, 2020): 834–40. http://dx.doi.org/10.1007/s00540-020-02821-8.

Full text
Abstract:
Abstract Purpose Tapentadol is a dual-acting mu-opioid receptor agonist and noradrenaline reuptake inhibitor with non-inferior analgesic efficacy to oxycodone and better gastrointestinal tolerability than full mu-opioid receptor agonists. Tapentadol is approved for cancer pain in Japan; however, real-world evidence on tapentadol’s effectiveness and safety for cancer-related pain in Japan is limited. Methods This retrospective study evaluated the effectiveness, safety, and tolerability of tapentadol (by patient type—opioid-naïve and opioid-tolerant) in 84 patients with moderate-to-severe cancer pain at Ichikawa General Hospital between September 2014 and August 2016. Results Almost 93% of patients achieved clinically relevant pain relief within 4 days (median). Over 90% of patients with neuropathic pain or mixed pain and all patients with nociceptive pain were responders. Pain intensity significantly decreased from baseline through to the end of maintenance period in opioid-naïve and opioid-tolerant patients. No patients discontinued tapentadol due to serious adverse events. No opioid-naïve patients experienced nausea or vomiting during tapentadol treatment. Only three opioid-tolerant patients experienced nausea which was considered to be related to tapentadol. Conclusion Tapentadol is effective and well tolerated in opioid-naïve and opioid-tolerant patients with cancer pain of varying pathophysiology, including those with nociceptive and/or neuropathic components. Tapentadol may be considered for first-line use in moderate-to-severe cancer-related pain.
APA, Harvard, Vancouver, ISO, and other styles
5

Richards, John R., Irina N. Richards, Gal Ozery, and Robert W. Derlet. "Droperidol Analgesia for Opioid-Tolerant Patients." Journal of Emergency Medicine 41, no. 4 (October 2011): 389–96. http://dx.doi.org/10.1016/j.jemermed.2010.07.005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Simpson, GK, and M. Jackson. "Perioperative management of opioid-tolerant patients." BJA Education 17, no. 4 (April 2017): 124–28. http://dx.doi.org/10.1093/bjaed/mkw049.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lin, Chih-Peng, Kai-Hsiang Kang, Tzu-Hung Lin, Ming-Yueh Wu, Houng-Chi Liou, Woei-Jer Chuang, Wei-Zen Sun, and Wen-Mei Fu. "Role of Spinal CXCL1 (GROα) in Opioid Tolerance." Anesthesiology 122, no. 3 (March 1, 2015): 666–76. http://dx.doi.org/10.1097/aln.0000000000000523.

Full text
Abstract:
Abstract Background: The pivotal role of glial activation and up-regulated inflammatory mediators in the opioid tolerance has been confirmed in rodents but not yet in humans. Here, the authors investigated the intraspinal cytokine and chemokine profiles of opioid-tolerant cancer patients; and to determine if up-regulated chemokines could modify opioid tolerance in rats. Methods: Cerebrospinal fluid samples from opioid-tolerant cancer patients and opioid-naive subjects were compared. The cerebrospinal fluid levels of tumor necrosis factor-alpha, CXCL1, CXCL10, CCL2, and CX3CL1 were assayed. The rat tail flick test was utilized to assess the effects of intrathecal CXCL1 on morphine-induced acute antinociception and analgesic tolerance. Results: CXCL1 level in cerebrospinal fluid was significantly up-regulated in the opioid-tolerant group (n = 30, 18.8 pg/ml vs. 13.2 pg/ml, P = 0.02) and was positively correlated (r2 = 0.49, P &lt; 0.01) with opioid dosage. In rat experiment, after induction of tolerance by morphine infusion, the spinal cord CXCL1 messenger RNA was up-regulated to 32.5 ± 11.9-fold. Although CXCL1 infusion alone did not affect baseline tail-flick latency, the analgesic efficacy of a single intraperitoneal injection of morphine dropped significantly on day 1 to day 3 after intrathecal infusion of CXCL1. After establishing tolerance by intrathecal continuous infusion of morphine, its development was accelerated by coadministration of CXCL1 and attenuated by coadministration of CXCL1-neutralizing antibody or CXCR2 antagonist. Conclusions: CXCL1 is up-regulated in both opioid-tolerant patients and rodents. The onset and extent of opioid tolerance was affected by antagonizing intrathecal CXCL1/CXCR2 signaling. Therefore, the CXCL1/CXCR2 signal pathway may be a novel target for the treatment of opioid tolerance.
APA, Harvard, Vancouver, ISO, and other styles
8

Bourne, Nicola. "Managing Acute Pain in Opioid Tolerant Patients." Journal of Perioperative Practice 18, no. 11 (November 2008): 498–503. http://dx.doi.org/10.1177/175045890801801105.

Full text
Abstract:
Managing acute pain in opioid tolerant patients can be a significant challenge. This article will provide an overview of the terminology used when managing acute pain in these patients. This understanding is essential to ensure adequate pain relief while avoiding opioid withdrawal. It is also crucial that these patients are identified and that sufficient peri- and postoperative pain management plans are formulated. This article will present an overview of the terms tolerance, physical dependence and addiction. The literature on the management of acute pain in opioid tolerant patients will be considered. Finally an audit that explores and compares the practises of a group of London hospitals, with regard to managing post-surgical pain in opioid-dependent patients will be discussed.
APA, Harvard, Vancouver, ISO, and other styles
9

Schulz, Rüdiger, Eva Seidl, and Albert Herz. "Opioid dependence in the guinea-pig myenteric plexus is controlled by non-tolerant and tolerant opioid receptors." European Journal of Pharmacology 110, no. 3 (April 1985): 335–41. http://dx.doi.org/10.1016/0014-2999(85)90561-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Wilson, Jennifer LC, Patricia A. Poulin, Robert Sikorski, Howard J. Nathan, Monica Taljaard, and Catherine Smyth. "Opioid Use among Same-Day Surgery Patients: Prevalence, Management and Outcomes." Pain Research and Management 20, no. 6 (2015): 300–304. http://dx.doi.org/10.1155/2015/897491.

Full text
Abstract:
OBJECTIVES: To determine whether the prevalence of opioid use among patients requiring elective same-day admission (SDA) surgery is greater than the 2.5% prevalence found in the general population. Secondary objectives were to assess compliance with expert recommendations on acute pain management in opioid-tolerant patients and to examine clinical outcomes.METHODS: A retrospective review of 812 systematically sampled adult SDA surgical cases between April 1, 2008 and March 31, 2009 was conducted.RESULTS: Among 798 eligible patients, 148 (18.5% [95% CI 15.9% to 21.2%]) were prescribed opioids, with 4.4% prescribed long-acting opioids (95% CI 3.0% to 5.8%). Use of opioids was most prevalent among orthopedic and neurosurgery patients. Among the 35 patients on long-acting opioids who had a high likelihood of being tolerant, anesthesiologists correctly identified 33, but only 13 (37%) took their usual opioid preoperatively while 22 (63%) had opioids continued postoperatively. Acetaminophen, nonsteroidal anti-inflammatory drugs and pregabalin were ordered preoperatively in 18 (51%), 15 (43%) and 18 (51%) cases, respectively, while ketamine was used in 15 (43%) patients intraoperatively. Acetaminophen, nonsteroidal anti-inflammatory drugs and pregabalin were ordered postoperatively in 31 (89%), 15 (43%) and 17 (49%) of the cases, respectively. No differences in length of stay, readmissions and emergency room visits were found between opioid-tolerant and opioid-naïve patients.CONCLUSION: Opioid use is more common in SDA surgical patients than in the general population and is most prevalent within orthopedic and neurosurgery patients. Uptake of expert opinion on the management of acute pain in the opioid tolerant patient population is lacking.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Opioid-tolerant"

1

Ahmad, Muhammad Imran. "A pilot study assessing fentanyl dose requirements in opioid-maintained individuals." Thesis, 2014. http://hdl.handle.net/2440/84137.

Full text
Abstract:
Pain is poorly managed in the opioid-maintained population. This study aimed to find safe and efficacious doses of fentanyl for acute pain management in the opioid-tolerant using experimental pain models and link that with the baseline morphine equivalent daily dose that the patients were taking. 9 patients were enrolled in the study from the Pain Management Unit at the Royal Adelaide Hospital. The study was an open label study using an infusion pump and STANPUMP software to rapidly achieve constant estimated effect compartment fentanyl concentrations. Fentanyl effect site concentrations of 2, 4, 6 and 8 ng/ml were targeted for the first visit and 4, 8, 12 and 16 ng/ml were targeted for patients on the second visit. The infusion involved four infusion steps lasting for 30 minutes each and during each step pharmacodynamic measures were taken that consisted of electroencephalography (EEG), saccadic eye movement test (SEM), pupillometry, morphine-benzedrine group scale (MBG) and cold pain test. The subjective opioid withdrawal scale tests (SOWS) were conducted once the infusion was stopped. Using PK/PD modelling techniques within R, the concentration-effect relationships were described using zero slope, linear, Emax [max subscript] and Sigmoid Emax [max subscript] models. Our study was not able to demonstrate that the baseline morphine equivalent daily dose predicted suitable doses of fentanyl in acute pain management of the opioid-tolerant. This was probably due to the fact that the study was of insufficient sample size to detect the effect of the covariate. However, we have demonstrated that the study design was safe, informative and suitable for it to be replicated with a larger number of subjects in the future.
Thesis (M.Phil.) -- University of Adelaide, School of Medical Sciences, 2014
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Opioid-tolerant"

1

Szabova, Alexandra, and Kenneth R. Goldschneider. Opioid-Tolerant Patient. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199764495.003.0043.

Full text
Abstract:
Caring for patients who are taking chronic opioids may present several challenges for clinicians in the operating room and in the immediate postoperative period. Factors such as tolerance and opioid-induced hyperalgesia can complicate perioperative pain management.
APA, Harvard, Vancouver, ISO, and other styles
2

Zelisko, Michael Blaine. The Opioid-Tolerant Patient. Edited by Erin S. Williams, Olutoyin A. Olutoye, Catherine P. Seipel, and Titilopemi A. O. Aina. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190678333.003.0036.

Full text
Abstract:
Caring for the opioid-tolerant patient presents several challenges in the perioperative period, including a higher incidence of anxiety, pain, and unanticipated hospital admission. The goal of the anesthesiologist is to provide sufficient analgesia while preventing withdrawal symptoms. This chapter reviews multimodal analgesia techniques, and addresses opioid tolerance, opioid-induced hyperalgesia, opioid rotation, and the use of methadone during the perioperative period.
APA, Harvard, Vancouver, ISO, and other styles
3

Yousefshahi, Fardin, Giuliano Michelagnoli, and Juan Francisco Asenjo. Ketamine Use and Opioid-Tolerant Cancer Patients. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190271787.003.0031.

Full text
Abstract:
Pain occurs in up to 70% of cancer patients and it can be challenging to manage. The standard for analgesic therapy is the World Health Organization ladder; however, up to 25% of patients don’t reach a level of comfort using this approach. Ketamine has been recognized as an excellent adjuvant for cancer pain treatment, especially when other analgesics have failed. Some randomized clinical trials have confirmed ketamine’s efficacy in refractory cancer pain, but most had small sample sizes and low power. Some publications have confirmed the beneficial effect of oral, intranasal, subcutaneous, or intravenous ketamine in treatment of refractory chronic cancer pain, while others are less conclusive. While ketamine is rapidly gaining ground as an adjuvant in treating pain in patients with cancers refractory to conventional therapy and/or patients with opioid tolerance, care should be taken to identify patients with ketamine contraindications in order to offer the greatest benefit with the lowest risk of side effects.
APA, Harvard, Vancouver, ISO, and other styles
4

Badiola, Ignacio, Tulsi Singh, Jiabin Liu, and Nabil Elkassabany. Acute Pain in the Opioid-Tolerant Patient. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190271787.003.0045.

Full text
Abstract:
The number of people addicted to prescription and illicit opioids continues to increase, and many of these patients present to the hospital or pain center with acute pain issues. The matter is further complicated by the increasing number of patients with legitimately painful conditions treated with chronic opioid therapy. Typically, these patients are difficult to manage during any acute pain episode due to their opioid tolerance and opioid-induced hyperalgesia. This difficulty often leads to inadequate pain management, increased suffering, and delayed hospital discharge. Increased awareness is needed among pain management physicians and other clinicians who care for opioid-tolerant patients, yet there is a lack of evidence-based medicine regarding the optimal treatment of this population.
APA, Harvard, Vancouver, ISO, and other styles
5

Kamal, Arif H., and Jason A. Webb. Effects of Morphine on Dyspnea (DRAFT). Edited by Nathan A. Gray and Thomas W. LeBlanc. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190658618.003.0016.

Full text
Abstract:
This chapter reports on an open, uncontrolled study to assess the effects of subcutaneous morphine on dyspnea in patients with terminal cancer. Twenty patients with dyspnea from restrictive respiratory failure received a subcutaneous dose of morphine relative to their opioid tolerance: 5mg for opioid naïve (5 patients) and 2.5 times regular dose for opioid tolerant (15 patients). Dyspnea and pain scores were measured every 15 minutes for 150 minutes. Dyspnea scores, but not respiratory rate, respiratory effort, nor arterial saturation of oxygen were affected. Ninety-five percent of patients reported improved dyspnea after morphine. This chapter describes the basics of the study and briefly reviews other relevant studies and information, gives a summary and discusses implications, and concludes with a relevant clinical case.
APA, Harvard, Vancouver, ISO, and other styles
6

Chen, Grace, and Ashley Valentine. Neuraxial Analgesia and Anesthesia in Chronic Opioid Users and Patients with Pre-existing Pain. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190457006.003.0007.

Full text
Abstract:
Neuraxial anesthesia and analgesia are effective modalities for surgery and perioperative pain management, respectively. These techniques may have nonanalgesic benefits as well, including improved 30-day mortality benefit, decreased risk of perioperative pneumonia, decreased risk of persistent postoperative pain, and attenuation of the stress response to surgery with improved survival in certain cancers. Post-operative pain control with epidural can be especially beneficial for opioid tolerant chronic pain patients compared to enteral or parenteral analgesics alone. In patients with previous back surgery or scoliosis, neuraxial techniques may be technically difficult. However, there is no evidence to suggest neuraxial approaches worsen pre-existing back pain. The exceptions are a pathology that reduces spinal canal cross-sectional area (e.g., severe spinal stenosis) and spinal infection. Neuraxial techniques should be avoided in these patients. Preprocedural labs and imaging are dictated by patient comorbidities, medication, and anatomy (e.g. scoliosis or spinal column pathology).
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Opioid-tolerant"

1

Dillane, Derek, and Chris Douglas. "The Opioid-Tolerant Patient." In Preoperative Assessment, 295–300. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-58842-7_47.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bautista, Alexander, Robert Liu, and Jianguo Cheng. "Comprehensive Pain Management: Opioid-Naïve Versus Opioid-Tolerant Patients." In Pain Control in Ambulatory Surgery Centers, 123–31. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-55262-6_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Jackson, Mark. "Acute Pain Management of Opioid-Tolerant Patients." In AAGBI Core Topics in Anaesthesia 2015, 28–38. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2015. http://dx.doi.org/10.1002/9781118777442.ch3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Patel, Darshan, and Dalia H. Elmofty. "A 35-Year-Old Opioid-Tolerant Patient with Uncontrolled Pain After Surgery." In Practical Chronic Pain Management, 381–88. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-46675-6_46.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Salaman, Nilda E., and May L. Chin. "The Opioid-Tolerant Pregnant Patient." In Pain in Women, 135–50. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199796410.003.0010.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Abel, Stephanie. "Pain Management in Opioid-Tolerant Patients." In Pain, 377–88. Oxford University Press, 2022. http://dx.doi.org/10.1093/med/9780197542873.003.0044.

Full text
Abstract:
The treatment of acute pain in patients who are opioid tolerant is a challenge. This pain is often acute on chronic and intensified by baseline tolerance and hyperalgesia from both the opioids and the chronic pain. This chapter reviews strategies for approaching acute pain assessment, optimizing non-opioid and nonpharmacologic therapies, and the importance of evaluating pain etiology, as well as an assessment of the concept of “total pain” and tailoring therapies accordingly. It will also address considerations for when pain is not resolved, or is even worsened, by escalating doses of opioid. The treatment of acute pain in patients on medication for opioid use disorder (MOUD) is outside the scope of this chapter. However, most concepts apply, and references are provided if further reading is needed to accommodate better insight on how to proceed with the inpatient management of the MOUD regimen.
APA, Harvard, Vancouver, ISO, and other styles
7

"Perioperative care of the opioid-tolerant patient." In Handbook of Acute Pain Management, 304–10. CRC Press, 2016. http://dx.doi.org/10.1201/b13785-20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

DE LEON-CASASOLA, OSCAR A. "Cancer Pain Management in the Opioid-Tolerant Patient." In Cancer Pain, 231–34. Elsevier, 2006. http://dx.doi.org/10.1016/b978-0-7216-0261-5.50024-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Gelfman, Laura P., and Emily J. Chai. "How Should Methadone Be Started and Titrated in Opioid-Naïve and Opioid-Tolerant Patients?" In Evidence-Based Practice in Palliative Medicine, 34–38. Elsevier, 2013. http://dx.doi.org/10.1016/b978-1-4377-3796-7.00007-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Roberts, Lindy J. "The opioid-tolerant patient, including those with a substance abuse disorder." In Clinical Pain Management, 539–57. CRC Press, 2008. http://dx.doi.org/10.1201/b13460-31.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Opioid-tolerant' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography